Biopharma group Lipoxen PLC (AIM: LPX) has been granted a new co-delivery DNA vaccine patent in the EU and the US for its ImuXen liposomal technology.
The new patent claims that ImuXen technology can induce a further enhanced immune response for vaccine delivery when the DNA and antigen components are combined together into the liposomal delivery system. This new patent is a sequel to Lipoxen's existing patent surrounding ImuXen where an improved immune response was demonstrated when DNA alone was entrapped in the liposome technology.
CEO Scott Maguire said: “We have several collaborations in place with some of the world's leading vaccine companies and further technology evaluation projects underway. We expect this new patent will strengthen our capability to collaborate with partners and we look forward to announcing progress on this front in due course.”
www.proactiveinvestors.com
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment